Filing Flows › Insight Molecular Diagnostics (IMDX) › Q4 2024
Insight Molecular Diagnostics (IMDX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 24, 2025
Insight Molecular Diagnostics (IMDX) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), +373% from a year earlier and up 13-fold from the quarter before.
Insight Molecular Diagnostics, Q4 2024: revenue $1.5M (+373% year over year), net loss $33.5M, operating cash flow −$5.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | 13× | +373% |
| Operating profit | −$33.6M | — | — |
| Net earnings | −$33.5M | — | — |
| Operating cash flow | −$5.4M | — | — |
What changed
Revenue was $1.5M in Q4 2024, up 373% year over year and up 1192% from the previous quarter.
Gross margin was 40.0%. Operating costs exceeded revenue by $33.6M, an operating margin of -2262.9%. The fastest-growing cost line was Other operating costs (+152%). The quarter ended with a net loss of $33.5M, wider than the previous quarter's $13.5M loss.
Operating cash flow was −$5.4M. Non-cash charges added back $563K of depreciation and amortization and $499K of share-based compensation. Working capital and other items added $27.1M. Capital expenditures of $214K exceeded it, leaving free cash flow of −$5.6M.
Questions
What was Insight Molecular Diagnostics' revenue in the fourth quarter 2024?
Insight Molecular Diagnostics (IMDX) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), +373% from a year earlier and up 13-fold from the quarter before.